CAS: 823-56-3; 2-Fluoro-3,5-Dichloropyridine

相似化合物

1480-64-4 1480-65-5 1214359-76-8

上下游产品

2,3,5-trichloropyridine tetra-n-°Ctylphosphonium bromide 3,5-dichloro-2-fluoro-4-iodopyridine methyl 2-[4-(3,5-dichloropyridin-2-yloxy)-phenoxy]-propionate ethyl 2-{p-[(3,5-dichloro-pyridin-2-yl)oxy]phenoxy}propionate 5-chloro-2,3-difluoropyridine

2,3,5-三氯吡啶置于potassium Fluoride体系中,用 环丁砜 作为反应溶剂,化学反应 20.0H,以86%的收率获得产物3,5-二氯-2-氟吡啶
参考文献:区域化学灵活性:2,3,5-三卤吡啶在 4 位或 6 位的选择性官能化
标题:区域化学灵活性:2,3,5-三卤吡啶在 4 位或 6 位的选择性官能化
摘要:使用 2,3,5-三氯吡啶,3,5-二氯-2-氟吡啶和 5-氯-2,3-二氟吡啶作为底物进行去质子化研究.与二异丙基氨基锂 (Lda) 反应后,去质子化仅发生在 4 位.随后的羧化和碘化产生酸和 4-碘吡啶.后者的曝光.对锂 2,2,6,6-四甲基哌啶 (Litmp) 造成去质子化并立即导致碘迁移.中间体用干冰捕获以提供羧酸.中和后得到6-碘吡啶.这些化合物.当用异丙基氯化镁处理时,很容易将重卤素换成金属.通过这种方式,可以在 6 位选择性地引入官能团.常规使用二氧化碳作为模型亲电试剂,形成了三卤代吡啶羧酸,目前尚不清楚,这将为药物研究提供有价值的新构建块.此外,2-位卤素的选择性亲核置换可以产生各种各样的新结构.[在 Scifinder (R) 上]
DOI:10.1002/1099-0690(200112)2001:23<4533::Aid-Ejoc4533>3.0.Co;2-1

专利信息

专利号:US-2023286918-A1
优先权日:2020-07-02
标 题:Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
发明人：JURKAUSKAS VALDAS; JUNG YOUNG CHUN; KWON TAESOO; KANNAN ARUNACHALAM; GONDI VIJAYA BHASKER
权利人:AKEBIA THERAPEUTICS INC
摘要:Disclosed herein are methods and processes of preparing vadadustat or a pharmaceutically acceptable salts thereof, and intermediates (e.g., a compound of Formula (I), (I-F), (II), or (IV), or a pharmaceutically acceptable salts thereof) useful for the synthesis of vadadustat.

专利号:EP-1437117-A1
优先权日:2002-12-19
标 题:Use of Sinapic acid and/or its derivatives
发明人：MOUSSOU PHILIPPE; DANOUX LOUIS; JEANMAIRE CHRISTINE; PAULY GILLES
权利人:COGNIS FRANCE SA
摘要:Use of sinapic acid and / or sinapic acid derivatives fornProduction of cosmetic and / or dermopharmaceutical preparationsnto protect against skin aging and wrinkling, especially throughnUV radiation, for the production of cosmetic and / orndermopharmaceutical preparations for delaying the aging ofnMitochondria, to protect the mitochondrial genome from oxidativenStress, to improve the energy production capacity of the humannSkin, the use of sinapic acid and / or sinapic acid derivatives fornProduction of cosmetic and / or dermopharmaceutical preparationsnto protect cellular DNA, to protect against thymine dimer formationnInfluence of UV-B radiation in skin cells and for the improvement ofnDNA repair mechanism in skin cells, to stimulate thenCollagen synthesis, as well as the use for the preparation of preparationsnfor wound healing after non-enzymatic glycosylation or influence ofnoxidative stress or environmental toxins.

专利号:WO-2022006427-A1
优先权日:2020-07-02
标题:Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat

专利号:US-10766863-B2
优先权日:2014-11-17
标 题 :Monocarboxylate transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT; WU QIONG
权利人:NIROGYONE THERAPEUTICS INC
摘要:The invention generally relates to the field of monocarboxylate transport modulators, e.g., monocarboxylate transport inhibitors, and more particularly to new substituted-quinolone compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in treating, modulating, forestalling and/or reducing physiological conditions associated with monocarboxylate transport activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, obesity, diabetes, cardiovascular diseases, tissue and organ transplant rejection, and malaria.

专利号:US-2011236330-A1
优先权日:2008-12-09
标 题:Skin Whitening
发明人：MOUSSOU PHILIPPE; SABADOTTO MELANIE; RATHJENS ANDREAS
权利人:MOUSSOU PHILIPPE; SABADOTTO MELANIE; RATHJENS ANDREAS
摘要:Methods for reducing pigmentation or hyperpigmentation of skin comprising applying to the skin a substance of formula (I) in the D-form, L-form or racemic form (D,L) are disclosed: n n n n n n n n n n whereinn R 1 is selected from the group consisting of a hydrogen group (—H), a methyl group (—CH 3 ), an ethyl group (—CH 2 CH 3 ), a C3 alkyl group, a C4 alkyl group, an acetyl group (—C(O)CH 3 ), a propanoyl group (—C(O)CH 2 CH 3 ), an n-butanoyl group (—C(O)CH 2 CH 2 CH 3 ), and a 2-methyl-propanoyl group (—C(O)CH(CH 3 ) 2 ), R 2 is selected from the group consisting of a hydrogen group (—H), an ethyl group (CH 2 CH 3 ), a C3 alkyl group, a C4 alkyl group, an acetyl group (—C(O)CH 3 ), a propanoyl group (—C(O)CH 2 CH 3 ), an n-butanoyl group (—C(O)CH 2 CH 2 CH 3 ), and a 2-methyl-propanoyl group (—C(O)CH(CH 3 ) 2 ), R 3 is selected from the group consisting of a hydroxyl group (—OH), an amino group (NH 2 ), a methoxy group (OCH 3 ), an ethoxy group (—OCH 2 CH 3 ), a C3 alkoxy group, a C4 alkoxy group, and a benzyloxy group (—OCH 2 C 6 H 5 ), and X and Y are independently selected from the group consisting of a hydrogen group (—H), a methyl group (—CH 3 ), an ethyl group (—CH 2 CH 3 ), a C3 group alkyl, a C4 alkyl group, a halogen group, a methoxy group (—OCH 3 ), an ethoxy group (—OCH 2 CH 3 ), a C3 alkoxy group, a C4 alkoxy group, and a benzyloxy group (—OCH 2 C 6 H 5 ), provided that at least one of X and Y is not a hydrogen group (—H). nn Cosmetic compositions and/or topical compositions comprising the substance are useful for (i) lightening of the skin and/or (ii) whitening of the skin and/or (iii) reduction of pigmentation of the skin and/or (iv) reduction of hyperpigmentation of the skin and/or (v) inhibition of melanogenesis in the skin and/or (vi) prevention and/or retardation of signs of ageing and/or improving the skin appearance of an aged skin. Such composition are also useful for treatment of pigmentation or hyperpigmentation of the skin due to abnormal melanin synthesis and/or secretion.